Contents Editor's Letter What to look forward to in GaBI Journal, 2013, Issue 2 Editorial National and regional activities by sickness funds in Austria to encourage the rational use of medicines Letters to the Editor Access to liposomal generic formulations: beyond AmBisome and Doxil/Caelyx Challenges to generic medicines utilization in Yemeni healthcare system Original Research…

The editors and publisher wish to express their gratitude to the colleagues listed below for their valuable contribution to the peer review process for the Generics and Biosimilars Initiative Journal (GaBI Journal) in 2013. Dr Ibrahim Aljuffali, Saudi Arabia Professor Saleh Alsuwayeh, Saudi Arabia Professor Alain Astier, France Dr Christoph Baumgärtel, Austria Professor Mohamed Izham Bin…

Contents Editor's Letter Latest features in GaBI Journal, 2013, Issue 3 Editorial Italy’s final position paper on biosimilars and new price and reimbursement pathway Commentary Commentary on the recommendations of the European Society for Organ Transplantation Advisory Committee on generic substitution of immunosuppressive drugs Biosimilar monoclonal antibodies—challenges and opportunities in Europe Ongoing initiatives in the…

The editors and publisher wish to express their gratitude to the colleagues listed below for their valuable contribution to the peer review process for the Generics and Biosimilars Initiative Journal (GaBI Journal) in 2014. Ms Arpah Abas, Malaysia Dr Christoph Baumgärtel, Austria Professor Daniel Kelly Benjamin Jr, USA Professor Gerrit Borchard, Switzerland Dr Chiann Chang, Brazil…

Contents Editor’s Letter Unmet potential of Generics and Biosimilars to reduce healthcare costs Original Research Pricing of oral generic cancer medicines in 25 European countries; findings and implications Review Article Are there biosimilar orphan drugs for Gaucher disease? An overview in Mexico Meeting Report 2nd MENA Stakeholder Meeting on Biosimilars 2018 – Report Abstracted Scientific…

Contents Editor’s Letter Fourth and final issue of GaBI Journal’s 10th volume Original Research Extended stability of the trastuzumab biosimilar ABP 980 (KANJINTI™) in polyolefin bags and elastomeric devices Review Article The European framework for intellectual property rights for biological medicines Biotechnological therapies and biosimilars for COVID-19: scarcities, poor regulation, and pharmaceutical black market: a…

Contents Editor’s Letter First 2022 GaBI Journal issue highlights Letter to Editor No need for systematic switch studies to demonstrate interchangeability of biosimilars Review Article Biotherapeutic products in the European Pharmacopoeia: have all challenges been tackled? Challenges in the manufacture, storage, distribution and regulation of traditional and novel vaccines Long-acting insulin analogues. Drug selection by…

Contents Editor's Letter GaBI Journal publishes four issues in 2013 Editorial Suggested evaluation of biological drugs role for WHO – Editor’s response Do low- to middle-income countries need a biosimilar approval pathway based on a full comparability exercise? Letters to the Editor Legislative efforts to limit prescription information sharing between patients and healthcare providers represent…

The editors and publisher wish to express their gratitude to the colleagues listed below for their valuable contribution to the peer review process for the Generics and Biosimilars Initiative Journal (GaBI Journal) in 2016. Dr Ali M Alhomaidan, Saudi Arabia Dr Srinivas Chollangi, USA Professor Joshua Cohen, USA Professor Daan J Crommelin, The Netherlands Professor Theodor…

The editors and publisher wish to express their gratitude to the colleagues listed below for their valuable contribution to the peer review process for the Generics and Biosimilars Initiative Journal (GaBI Journal) in 2015. Professor Saleh Alsuwayeh, Saudi Arabia Professor Moses Chow, USA Associate Professor Joshua P Cohen, USA Professor Theodor Dingermann, Germany Dr Niklas Ekman, Finland…

Contents Editor’s Letter Latest features in GaBI Journal, 2016, Issue 3 Letters to the Editor Is the EU ready for non-biological complex drug products? Commentary Biosimilars: achieving long-term savings and competitive markets Review Article Current state of subsequent entry biologics (biosimilars) in Canada: a view from regulatory, reimbursement, clinician, and patient perspectives The generic medicines…

The editors and publisher wish to express their gratitude to the colleagues listed below for their valuable contribution to the peer review process for the Generics and Biosimilars Initiative Journal (GaBI Journal) in 2018. Professor Othman Alshabanah, Saudi Arabia Dr Ahmet Bosnak, Turkey Professor Moses SS Chow, USA Professor Theodor Dingermann, Germany Professor Jaime Espin,…